Marketplace eNewsletter Bi-Monthly | Having trouble viewing this e-mail? Click here. |
|
Pharmaceutical Sciences, Manufacturing & Marketplace Report August 28, 2013 |
From Cynthia Challener, PhD, Editor, Pharmaceutical Sciences, Manufacturing & Marketplace Report In this issue, researchers from Millennium: The Takeda Oncology Company employ memory of chirality to install a chiral quarternary carbon center in the large-scale preparation of a new TORC1/2 inhibitor. Also, UCLA researchers develop nanoencapuslation technology that may emable targeted delivery of injectable biopharmaceutical therapies. Plus reports on an accessible cell-imaging system that provides rich cellular visualization analysis, porous silica gel glidants for direct tablet compression of moisture-sensitive APIs, and single-use systems at Catalent Pharma Solutions' new biomanufacturing facility. |
||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ![]() |
|
|
![]() |
| Subscribe | Send Feedback | Advertise With Us | Visit pharmabiomarketplace.com | |
![]() |